Home > Healthcare > Drug Device Combination > Therapeutic Systems > Guillain-Barre Syndrome (GBS) Market

Guillain-Barre Syndrome (GBS) Market Trends

Report ID: GMI9361
Published Date: May 2024
Report Format: PDF

Download Free Sample

Guillain-Barre Syndrome Market Trends

The expanding elderly demographic has been a significant driver for the growth of the GBS market, with increasing numbers of the elderly population contributing to higher demand for diagnosis, treatment, and management of the condition. According to the World Health Organization's 2021 forecast by 2030, one in six individuals worldwide will be over 60, with their numbers expected to grow from 1 billion in 2020 to 2.1 billion by 2050. The elderly population, particularly those over 80, is projected to triple to 426 million by 2050. The rise in the demographic are prone to GBS, thereby the demand for novel treatment options increases which in turn spur the market growth.

A study published in the Journal of Neuroinflammation in November 2021 revealed that the risk and impact of GBS increase with age, particularly affecting more males across all age groups. This comprehensive analysis from 1990 to 2019 across 204 countries shows a clear trend that could significantly boost market growth in the forthcoming years.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Guillain-Barre syndrome industry size recorded USD 645.2 million in 2023 and will exhibit a 4.6% CAGR between 2024 and 2032 due to the increasing prevalence of autoimmune diseases, growing healthcare infrastructure, and rising healthcare expenditure.

The first-line treatment segment in the Guillain-Barre syndrome industry will register 4.8% CAGR till 2032, driven by the crucial role of initial therapies, such as intravenous immunoglobulin and plasma exchange, in managing the condition effectively.

North America Guillain-Barre syndrome industry size was USD 305.4 million in 2023, owing to advanced healthcare infrastructure, heightened awareness, and extensive R&D activities in the region.

Key Guillain-Barre syndrome industry players are AbbVie Inc., Biogen Inc., Cadila Healthcare Limited., CSL Behring LLC, F. Hoffmann-La Roche Ltd., GSK plc, Grifols SA, LGM Pharmaceuticals Inc., Merck & Co. Inc., Pfizer Inc., and Takeda Pharmaceutical Company Limited., among others.